Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Novel therapeutic concepts in multiple myeloma

Novel therapeutic concepts in multiple myeloma Treatment of multiple myeloma (MM) has evolved greatly over the past decade, and owing to immunomodulatory agents (thalidomide and lenalidomide) and proteasome inhibition (bortezomib), patients with MM enjoy prolonged survival and improved quality of life. Use of these novel agents has improved the rate of complete remissions in MM, a parameter that has emerged as an important step towards improved survival. Bortezomib should now be considered as an established component of the induction treatment prior to autologous transplantation in younger patients. The combination of melphalan/prednisone with a novel agent is a new standard of care for elderly patients with MM. The beneficial effect of these treatment approaches is also seen in special MM populations, in particular in those with impaired renal function and high-risk cytogenetic features. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Novel therapeutic concepts in multiple myeloma

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/novel-therapeutic-concepts-in-multiple-myeloma-GjnpulaUZd
Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-009-0096-8
Publisher site
See Article on Publisher Site

Abstract

Treatment of multiple myeloma (MM) has evolved greatly over the past decade, and owing to immunomodulatory agents (thalidomide and lenalidomide) and proteasome inhibition (bortezomib), patients with MM enjoy prolonged survival and improved quality of life. Use of these novel agents has improved the rate of complete remissions in MM, a parameter that has emerged as an important step towards improved survival. Bortezomib should now be considered as an established component of the induction treatment prior to autologous transplantation in younger patients. The combination of melphalan/prednisone with a novel agent is a new standard of care for elderly patients with MM. The beneficial effect of these treatment approaches is also seen in special MM populations, in particular in those with impaired renal function and high-risk cytogenetic features.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jan 1, 2009

References

  • The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies
    Mitsiades, CS; McMillin, DW; Klippel, S; Hideshima, T
  • Thalidomide for treatment of multiple myeloma: 10 years later
    Palumbo, A; Facon, T; Sonneveld, P; Blade, J
  • Lenalidomide: a new therapy for multiple myeloma
    Palumbo, A; San Miguel, J; Sonneveld, P; Moreau, P
  • Targeting proteasomes as therapy in multiple myeloma
    Chauhan, D; Hideshima, T; Anderson, KC
  • Proteasome inhibition as a novel therapeutic target in human cancer
    Rajkumar, SV; Richardson, PG; Hideshima, T; Anderson, KC
  • International Staging System for multiple myeloma
    Greipp, PR; San Miguel, J; Durie, BGM; Crowley, JJ
  • Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART)
    Dispenzieri, A; Rajkumar, V; Gertz, MA; Fonseca, R
  • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
    Attal, M; Harousseau, JL; Stoppa, AM; Sotto, JJ
  • The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma. Combined results of the IFM 99 trials
    Harousseau, JL; Attal, M; Moreau, P; Garban, F
  • Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study
    Cavo, M; Tosi, P; Zamagni, E; Cellini, C
  • Complete remission represents the major surrogate marker of long survival in multiple myeloma
    Wang, M; Delasalle, K; Thomas, S; Giralt, S; Alexanian, R
  • Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation
    Kyle, RA; Leong, T; Li, S; Oken, MM
  • The effects of induction chemotherapy and high-dose melphalan with tandem autologous transplantation in multiple myeloma: the prospective randomized DSMM 2 study
    Straka, C; Liebisch, P; Hennemann, B; Metzner, B
  • Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation in previously untreated multiple myeloma: updated data from IFM 2005/01 trial
    Harousseau, JL; Mathiot, C; Attal, M; Marit, G
  • Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) in preparation for autologous stem-cell transplantation in newly diagnosed multiple myeloma
    Cavo, M; Patriarca, F; Tacchetti, P; Galli, M
  • Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival and outcome
    Rajkumar, SV; Jacobus, S; Callander, N; Fonseca, R
  • Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral stem cell transplantation in patients with newly diagnosed myeloma
    Kumar, S; Dispenzieri, A; Lacy, MQ; Hayman, SR
  • Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma
    Paripati, H; Stewart, AK; Cabou, S; Dueck, A
  • Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
    Mark, T; Stern, J; Furst, JR; Jayabalan, D
  • Melphalan and prednisone plus thalidomide versus melphalan plus prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial
    Facon, T; Mary, JH; Hulin, C; Benboubker, L
  • Melphalan-prednisone-Thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with Melphalan-Prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01
    Hulin, C; Facon, T; Rodon, P; Pegourie, B
  • Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
    Palumbo, A; Bringhen, S; Liberati, AM; Caravita, T
  • A randomized placebo controlled study with melphalan/prednisone vs melphalan/prednisone/thalidomide: quality of life and toxicity
    Gulbrandsen, N; Waage, A; Gimsing, P; Turesson, I
  • Melphalan+prednisone vs melphalan+prednisone+thalidomide in induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON
    Wijermans, P; Schaafsma, M; van Norden, Y; Ammerlaan, R
  • Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Barlogie, B; Tricot, G; Anaissie, E; Shaughnessy, J
  • Thalidomide-Dexamethasone vs. Melphalan-Prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma
    Ludwig, H; Tothova, E; Hajek, R; Drach, J
  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    San Miguel, J; Schlag, R; Khuageva, N; Dimopoulos, M
  • Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
    Attal, M; Harousseau, JL; Leyvraz, S; Doyen, C
  • Single autologous transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
    Abdelkefi, A; Ladeb, S; Torjman, L; Othman, TB
  • Recovery of renal impairment by bortezomib-doxorubicin-dexamethasone (BDD) in multiple myeloma patients with acute renal failure. Results from an ongoing phase II study
    Ludwig, H; Adam, Z; Greil, R; Keil, F
  • Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens
    Roussou, M; Kastritis, E; Migkou, M; Psimenou, E